Skip to main content

Human CXCL16 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB976

R&D Systems, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Mouse

Applications

Validated:

CyTOF-ready, Flow Cytometry, Neutralization, Western Blot

Cited:

Neutralization

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG2A Clone # 256213

Product Specifications

Immunogen

E. coli-derived recombinant human CXCL16
Asn30-Pro118
Accession # Q9H2A7.4

Specificity

Detects human CXCL16 in direct ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant human CXCL1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12/SDF-1 alpha,12/SDF-1 beta, 13, recombinant mouse CXCL1, 2, 6, 9, 10, 12/SDF-1 alpha, 13, 16, recombinant rat CXCL1, 2, 3/CINC-2 alpha, 3/CINC-2 beta, recombinant canine CXCL8, or recombinant porcine CXCL8 is observed.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2A

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human CXCL16 Antibody

Chemotaxis Induced by CXCL16 and Neutralization by Human CXCL16 Antibody.

Chemotaxis Induced by CXCL16 and Neutralization by Human CXCL16 Antibody.

Recombinant Human CXCL16 Chemokine Domain (Catalog # 976-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with mouse CXCR6 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL16 Chemokine Domain (20 ng/mL) is neutralized (green line) by increasing concentrations of Human CXCL16 Monoclonal Antibody (Catalog # MAB976). The ND50 is typically 2-8 µg/mL.

Applications for Human CXCL16 Antibody

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

2.5 µg/106 cells
Sample: Human monocyte-derived dendritic cells

Western Blot

1 µg/mL
Sample: Recombinant Human CXCL16 Chemokine Domain (Catalog # 976-CX) under non-reducing conditions only

Neutralization

Measured by its ability to neutralize CXCL16-induced chemotaxis in the BaF3 mouse pro-B cell line transfected with mouse CXCR6. Matloubian, M. et al. (2000) Nature Immunol. 1:298. The Neutralization Dose (ND50) is typically 2-8 µg/mL in the presence of 20 ng/mL Recombinant Human CXCL16 Chemokine Domain.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL16

CXCL16 is a transmembrane protein with an extracellular domain consisting of a chemokine domain suspended on a mucin-like stalk. It functions as a ligand for the HIV co‑receptor, CXCR6 (Bonzo).

Alternate Names

CXCL16

Entrez Gene IDs

58191 (Human); 66102 (Mouse)

Gene Symbol

CXCL16

UniProt

Additional CXCL16 Products

Product Documents for Human CXCL16 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human CXCL16 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...